Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 9:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Narcolepsy Type 2 (NT2) Clear all
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2)
Interventions
TAK-994, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
36
States / cities
Alabaster, Alabama • Phoenix, Arizona • Bellflower, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced May 21, 2026, 9:40 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Narcolepsy
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
17
States / cities
Santa Ana, California • Brandon, Florida • Medley, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 9:40 PM EDT
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions
ALKS 2680, 4mg, ALKS 2680, 6mg, ALKS 2680, 8mg, ALKS 2680, 10mg, ALKS 2680, 14mg, ALKS 2680, 18mg
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
30
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced May 21, 2026, 9:40 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Narcolepsy Type 2
Interventions
TAK-360, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
12
States / cities
Redwood City, California • Santa Ana, California • Colorado Springs, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced May 21, 2026, 9:40 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Narcolepsy Type 2
Interventions
ALKS 2680 Dose 1, ALKS 2680 Dose 2, ALKS 2680 Dose 3, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Brandon, Florida • Macon, Georgia • Lansing, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 21, 2026, 9:40 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions
ORX750
Drug
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
19
States / cities
Auburn, Alabama • Santa Ana, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 21, 2026, 9:40 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Narcolepsy Type 2
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
33
States / cities
Little Rock, Arkansas • Los Angeles, California • Redwood City, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 9:40 PM EDT